Results: Of the 117 patients who lost weight before baseline, 63% maintained or gained weight. In patients receiving dronabinol for 1 year, the mean weight gain (± SD) was 3.7 ± ± 10.6 lb. The percentage of patients experiencing loss of appetite decreased significantly from 71% at baseline to 26% at 1 month (P < < .001) and continued to decline throughout the trial. The percentage of patients experiencing nausea at baseline (38%) decreased consistently from week 2 on; this change from baseline was significant at month 6 (P = = .031). Conclusion: When taken for 3 months to 1 year, dronabinol significantly improves appetite and reverses weight loss in patients living with HIV/AIDS.
Introduction
HIV wasting syndrome, first described by the Centers for Disease Control in 1987, 1 is an AIDS-defining illness that consists of the involuntary loss of more than 10% of baseline body weight and is associated with chronic diarrhea, weakness, or fever in the absence of a concurrent condition other than HIV. 1, 2 A recently revised definition of HIV-associated wasting stipulates that a patient must fulfill one of the following criteria: unintentional weight loss of 10% or more over 12 months, unintentional weight loss of 7.5% or more over 6 months, body cell mass loss of 5% or more over 6 months (less than 35% of total body weight for men and less than 23% for women), and a body mass index (BMI) < 20 kg/m 2 . 3 Although the incidence of HIV-related wasting appears to have declined since the advent of highly active antiretroviral therapy (HAART), weight loss and wasting are still common complications in patients with HIV and continue to be regarded as significant clinical complications. [4] [5] [6] [7] [8] According to a prospective analysis from a large cohort of HIV-infected patients participating in the Nutrition for Healthy Living study, about one third of study participants met at least one criterion of HIV wasting, despite the fact that more than 50% of the cohort was receiving HAART. 8 Based on a review of data accumulated since 1989, it has been estimated that the risk of death in an HIVinfected patient who loses 5% to 10% of his or her baseline body weight may be as much as 2.5 times that of a patient who does not lose weight. 9 Weight loss (and malnutrition) in HIV-infected patients can also dramatically increase the morbidity associated with opportunistic infections in addition to contributing to disability and reducing perceived quality of life. [9] [10] [11] [12] Hence, a major goal in the treatment of patients living with HIV/AIDS is to prevent weight loss or wasting. Among the many agents used for this purpose are appetite stimulants and products used to increase weight, such as megestrol, cannabinoids, anabolic steroids, and recombinant human growth hormones. 7, 13, 14 Appetite stimulants have been shown to increase appetite, maintaining weight status and improving nutritional status. 6, [15] [16] [17] Dronabinol (synthetically produced delta-9-tetrahydrocannabinol) is currently indicated for the treatment of anorexia associated with weight loss in patients with AIDS, and nausea and vomiting associated with cancer chemotherapy in patients in whom conventional antiemetic treatments has failed. 18 A number of studies in patients living with HIV/AIDS have demonstrated that dronabinol significantly increases appetite and maintains (or even significantly increases) body weight, in addition to decreasing nausea and improving mood. [19] [20] [21] [22] [23] A recent study of 67 patients with HIV-1 infection on stable antiretroviral therapy demonstrated that dronabinol produced a significant increase in body weight compared with placebo. 23 Dronabinol did not compromise the safety of the protease inhibitors (ie, indinavir and nelfinavir) that were used; there were no significant changes in the patients' viral loads or CD4/CD8 counts, nor were there any clinically significant alterations in the blood levels of indinavir or nelfinavir.
In this retrospective analysis, we evaluated the effects of dronabinol on body weight, loss of appetite, nausea, and vomiting in patients with HIV/AIDS who were treated with dronabinol between January 1993 and March 2003. A secondary objective was to assess the safety and tolerability of dronabinol.
Methods

Study Design
This is a retrospective analysis of data from a cohort of patients living with HIV/AIDS who were prescribed dronabinol (Marinol, Solvay Pharmaceuticals, Inc) for various reasons, including loss of appetite, weight loss, nausea, and emesis.
Patients
All patients were seen at 5 medical centers in the United States, had a confirmed diagnosis of HIV/AIDS, and received dronabinol for 3 to 12 months from January 11, 1993 , through March 17, 2003 . Antiretroviral agentnaive patients were eligible for inclusion if they were scheduled to begin HIV/AIDS therapy at the baseline visit. Patients were required to have a minimum of 3 months of follow-up data and were excluded from the analysis if 1 or more of the following 3 key data points were missing: (1) maximum weight over the 12 months before initiation of dronabinol therapy, (2) baseline body weight, and/or (3) body weight at the 3-month or later follow-up.
Data Collection
A retrospective tool for data collection was designed for this study and completed by the investigators at each site using consecutively selected patients' charts. Requested data encompassed (1) indications for dronabinol, (2) prescribed dose of dronabinol, (3) maximum weight in the 12 months before initiation of dronabinol therapy, (4) baseline weight (and height, for calculation of BMI), (5) body weight at each followup visit, (6) presence or loss of appetite, nausea, or emesis at each follow-up visit, (7) concomitant medications taken at each study visit; and (8) dronabinol-related adverse events (AEs) reported at each follow-up visit.
Outcome Measures
The main outcome measures used in this analysis were (1) changes from baseline in body weight and BMI and (2) changes in the incidence of loss of appetite, nausea, and emesis during the course of dronabinol therapy. In addition, the patients' overall changes in weight from their 12-month maximum before the start of dronabinol therapy to their baseline and final follow-up visits were recorded.
Statistical Analyses
The body weight and BMI data for all eligible patients were summarized by study visit (ie, pretherapy maximum; baseline; week 2; months 1, 2, 3, and 6; and year 1). The statistical significance of the overall changes in patients' body weights during dronabinol therapy was assessed using paired t tests. Changes in weight from baseline (and from the maximum weight in the 12 months before dronabinol therapy) to the last visit were calculated for each patient, and the mean changes over all patients were tested to determine whether they differed from zero. The overall changes in patients' BMI scores were also assessed in a similar fashion. To assess whether the effect of dronabinol on body weight was influenced by changes in body weight before treatment, a 3 × 3 table was constructed by categorizing patients according to whether they lost, maintained, or gained weight during the 12 months before and during dronabinol therapy. The incidence of appetite loss, nausea, and emesis was summarized by study visit, and P values were calculated for the difference between the proportions of patients reporting loss of appetite, nausea, and emesis at baseline and the proportions at each study visit.
Total daily dose of dronabinol, which was calculated by multiplying the prescribed dose by the daily regimen, was summarized by study visit. Concomitant medications and dronabinol-related AEs were also summarized by study visit.
Results
Patient Characteristics
Of the 171 patients' charts originally reviewed, 155 patients were eligible for inclusion (Table 1) . Sixteen patients were excluded from the analysis because of missing data on their maximum weight during the 12 months before baseline, their baseline body weight, and/or their body weight during at least one 3-month or longer follow-up visit. The majority of the patients were already receiving antiretroviral therapies at baseline, but 15 (10%) were antiretroviral-naive. The number and proportion of patients with a minimum of 3-, 6-, and 12-month follow-up data were 13 (8%), 29 (19%) , and 113 (73%), respectively.
Individual indications for prescribing dronabinol were loss of appetite (n = 110, 71%), weight loss (n = 86, 55%), nausea (n = 59, 38%), emesis or vomiting (n = 18, 12%), and other (n = 8, 5%). Because many patients received dronabinol for more than one indication, the number of patients with an individual indication adds up to more than 100%. The overall indications were loss of appetite and weight loss (23%); loss of appetite, weight loss, and nausea (11%); loss of appetite and nausea (8%); and various other combined indications.
Because dronabinol was prescribed on an asneeded basis at 10% of patient visits, the total daily dose was unknown for this small subset of patients. However, the prescribed dosage regimen was known for the remaining 90% of patient visits. Based on these available data, the total mean daily dose of dronabinol prescribed at each visit ranged from 9.6 to 10.8 mg/day, except at the 1-year visit, when the total mean dose was 12.1 mg/day.
Of the 90% of patients receiving anti-HIV therapy, the majority was taking 2 to 4 antiretroviral agents, the most common of which were lamivudine/zidovudine and stavudine. The majority of patients were not taking antinausea/antiemetic agents or testosterone/nutritional supplements at each follow-up visit. Overall, there was little or no change in the number or types of HIV/AIDS therapies, antinausea/antiemetic agents, or testosterone/nutritional supplements taken by the patients throughout the follow-up period. However, the percentage of patients taking an antidepressant and/or anxiolytic agent increased by approximately 15% during the 1-year follow-up period.
A total of 34 (22%) of the 155 eligible patients discontinued dronabinol therapy during their follow-up period. Of the patients who discontinued dronabinol therapy, the most common recorded reason for treatment discontinuation was improvement of symptoms (n = 16). Other reasons were intolerance (n = 4), lack of efficacy (n = 3), were or economic issues (n = 1), and various other or unknown reasons (n = 10). Table 2 shows that there was a decrease from the mean maximum body weight during the 12 months before starting dronabinol therapy, followed by increases in mean weight at most study visits, beginning at week 2. Analysis of individual patient data using paired t tests showed that, overall, patients lost (mean ± SD) 7.5 ± 9.2 lb before baseline (t = 0, df = 154, P < .0001). Compared with baseline, the patients gained an overall average of 2.9 ± 10.7 lb during dronabinol therapy (t = 3.43, df = 154, P = .008). At the final visit, however, there was a significant deficit of 4.6 ± 13.5 lb (t = 4.21, df = 154, P < .001) compared with the previous 12-month maximum weight. The mean weight gain in the 113 patients who received dronabinol for 1 year (3.7 ± 10.6 lb) was not significantly different (P = .203) from the weight gain in the 13 patients who received dronabinol for only 3 months (1.4 ± 12.2 lb).
Changes in Weight
A total of 117 (75%) patients lost weight during the 12 months before starting dronabinol therapy, whereas 38 (25%) maintained their weight or gained weight during this period (Table 3) . Of the 117 patients who had previously lost weight, 73 (62%) gained weight while receiving dronabinol. Overall, 97 (63%) patients either maintained their weight or gained weight during treatment with dronabinol, irrespective of their previous weight status.
Changes in Body Mass Index
Body mass index was calculated in the 107 patients whose height was provided by the investigator. In general, the changes in patients' BMI scores paralleled the changes in body weight. Analysis of individual patient data using paired t tests showed that, before baseline, the patients' BMI scores decreased significantly by an average of 1.2 ± 1.3 points (t = 9.67, df = 106, 
Dronabinol Reverses Weight Loss in HIV/AIDS-Infected Patients
Changes in Loss of Appetite, Nausea, and Emesis
At baseline, 110 (71%) patients experienced a loss of appetite, 59 (38%) patients experienced nausea, and 17 (11%) patients experienced emesis ( Table 4 ). The percentage of patients experiencing loss of appetite decreased significantly (P < .001) from 71% at baseline by month 1 and remained lower than baseline throughout the follow-up period. The percentage of patients experiencing nausea decreased consistently beginning on week 2 and throughout the observation period, and the change was significant (P = .031) at month 6. There was also a decrease, although not significant, in the incidence of emesis from baseline to the final visit.
Safety Table 5 presents the percentage of patients who reported dronabinol-related AEs at each study visit. The overall incidence of dronabinol-related AEs was very low during the 1-year study period, and the majority of those involved the central nervous system. The highest incidence of AEs was observed at the month 2 visit (at which time 6/80, or 8%, of patients reported a total of 10 AEs) and at the month 6 visit (at which time 6/113, or 5%, of patients reported a total of 13 AEs). There was little or no change in the overall number and type of AEs reported during the 1-year follow-up period.
Discussion
Although the incidence of HIV wasting syndrome appears to have decreased since the introduction of HAART in 1995, 5, 24 weight loss and wasting continue to be common complications in patients with HIV/AIDS, with important implications with respect to morbidity and mortality. 8, [25] [26] [27] [28] Although numerous factors can contribute to weight loss and wasting in HIV/AIDS patients, 10, 13, 25, 29 the nutritional deficiency that ensues can compromise the body's ability to mount an immune response and increase susceptibility to opportunistic infections. 10, 12 The results of the present retrospective analysis are consistent with previous studies demonstrating that dronabinol was effective in improving HIV/AIDSassociated anorexia and other gastrointestinal (GI) symptoms. [19] [20] [21] [22] [23] [30] [31] [32] Because a patient's nutritional status is considered one of the key determinants of survival in HIV patients, 33 the fact that GI side effects are among the most common adverse reactions to antiretroviral therapy is of some concern. Using dronabinol to counteract weight loss and the loss of appetite might improve patients' nutritional status and improve survival.
The patients included in this study had lost a significant amount of weight (average, 7.5 lb) from their maximum weight during the preceding 12 months. During the subsequent 3 to 12 months of treatment with dronabinol, however, the patients gained an average of 2.9 lb from baseline to their final follow-up visit. Of note, the 113 patients who received dronabinol for 12 months gained an average of 3.7 lb. Of the 117 patients who had lost weight in the 12 months before starting dronabinol therapy, 62% gained weight while receiving dronabinol therapy. Furthermore, of the 29 patients who had maintained their prior maximum weight, 48% also gained weight during dronabinol therapy. Irrespective of their previous weight status, 63% of patients maintained their weight or gained weight during treatment with dronabinol. The majority of patients were not receiving testosterone or any nutritional supplements that could indirectly have contributed to the weight gain during the course of the observation period. Furthermore, dronabinol does not adversely affect CD4 or CD8 counts in patients with HIV infection. 23 The results of the present analysis should be interpreted with caution because a potential for selection bias is inherent to retrospective studies. However, the results are consistent with those reported by Beal et al in a randomized, placebo-controlled trial and its openlabel extension demonstrating consistent increases in weight gain in dronabinol-treated patients with AIDS. 21, 22 The patients who participated in the controlled trial were required to be in the advanced stages of AIDS, whereas this retrospective analysis included patients who were not selected on the basis of the stage of their HIV infection. Ten percent of patients in this retrospective analysis were antiretroviralnaive at baseline. Although 75% of patients included in this retrospective analysis lost weight during the 12 months before starting dronabinol therapy, this was not an inclusion criterion. Patients in the controlled trial 21, 22 were required to have lost a specified 2.3 kg or more from their normal body weight; therefore, the patients included in this retrospective analysis may represent a population with a broader spectrum of HIV infections and might thus be more representative of those patients typically seen in clinical practice. Another limitation of this uncontrolled trial is that patients were given HAART, which has an excellent record in reversing wasting. However, recent reports indicate that even in patients given HAART, weight loss and wasting remain important conditions. 3, 8, 26, 28 Because of the retrospective nature of this study, it is unknown whether the patients were consistently taking dronabinol throughout the active study period. Also, considering that weight, body composition, and activity level are known to vary in populations as they age, perhaps this study has more relevance to the present HIV patient population.
In conclusion, overall, 63% of patients maintained their weight or gained weight during treatment with dronabinol, irrespective of their previous weight status. Incidence of loss of appetite decreased significantly from 71% at baseline to 26% at month 1 and continued to decline throughout the follow-up period. Incidence of nausea decreased significantly from 38% at baseline to 25% by month 6. Our findings from this retrospective analysis are consistent with, and expand upon, published clinical trial data suggesting that dronabinol is well tolerated, increases appetite, and improves weight loss in HIV/AIDS patients experiencing these common disease manifestations.
